AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11265938 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized diabetes monitoring system (DMS)
Number of subjects: 19
Study 11265938 — intervention group
Group type: COMPARATOR
Intervention: Control period (no DMS)
Number of subjects: 19
Study 11265938 — intervention group
Group type: EXPERIMENTAL
Intervention: DMS acceptance
Number of subjects: 19
Study 9533608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardness meter measurement by Observer 1
Number of subjects: 20
Study 9533608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardness meter measurement by Observer 2
Number of subjects: 20
Study 9533608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardness meter measurement at standardized point
Number of subjects: 20
Study 9533608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardness meter measurement between observers
Number of subjects: 20
Study 9533608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardness meter measurement at 3 anatomical locations
Number of subjects: 20
Study 9533608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hardness meter measurement at 3 different speeds
Number of subjects: 20
Study 7798371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 20
Study 7798371 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic medication regimen
Number of subjects: 20
Study 2904696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (vitamin E)
Number of subjects: 15
Study 2904696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2904696 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpson-Angus Scale for Extrapyramidal Side Effects
Number of subjects: 15
Study 6125345 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg chlormezanone
Number of subjects: 55
Study 6125345 — intervention group
Group type: COMPARATOR
Intervention: 20 mg temazepam
Number of subjects: 55
Study 31475608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator (HFS group, n=36)
Number of subjects: 71
Study 31475608 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity simulator (LFS group, n=35)
Number of subjects: 71
Study 29246277 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation (6 g·d‐1 for 28 days)
Number of subjects: 26
Study 29246277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study 26386159 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 479
Study 26386159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant treatment
Number of subjects: 479
Study 24835860 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol and 600 mg ibuprofen administered one hour before the procedure
Number of subjects: 200
Study 24835860 — intervention group
Group type: COMPARATOR
Intervention: No medication administered
Number of subjects: 200
Study 23055505 — intervention group
Group type: EXPERIMENTAL
Intervention: Central stimulus moving at fast speed in the direction opposite to the surround
Number of subjects: 0
Study 23055505 — intervention group
Group type: COMPARATOR
Intervention: Central stimulus moving in the same direction as the surround at a speed such that it appeared stationary
Number of subjects: 0
Study 23055505 — intervention group
Group type: EXPERIMENTAL
Intervention: Early visual areas (V1, V2, V3, and V3A)
Number of subjects: 0
Study 19641359 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (50 mg/day)
Number of subjects: 95
Study 19641359 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 95
Study 17123473 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 1914
Study 17123473 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 1914
Study 15198449 — intervention group
Group type: COMPARATOR
Intervention: Cortical relay time (CRT) in control subjects
Number of subjects: 28
Study 15198449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical relay time (CRT) in patients with MS
Number of subjects: 28
Study 12503232 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nutrition program
Number of subjects: 238
Study 12503232 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison children)
Number of subjects: 238
Study 9832296 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel (10 mg)
Number of subjects: 0
Study 9832296 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac gel (10 mg)
Number of subjects: 0
Study 9832296 — intervention group
Group type: COMPARATOR
Intervention: Topical piroxicam gel (10 mg)
Number of subjects: 0
Study 9832296 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 8017592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 10
Study 8017592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2670419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate
Number of subjects: 20
Study 2670419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanoic acid
Number of subjects: 20
Study 2670419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid
Number of subjects: 20
Study 2670419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineering methods (TEWL and electrical conductance)
Number of subjects: 20
Study 2670419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineering methods (blood flow and skin thickness)
Number of subjects: 20
Study 792844 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG)
Number of subjects: 20
Study 792844 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antilymphocyte globulin (ALG) and thoracic duct drainage (TDD)
Number of subjects: 20
Study 792844 — intervention group
Group type: COMPARATOR
Intervention: Thoracic duct drainage (TDD)
Number of subjects: 20
Study 30181363 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind tracheal suctioning plus cleaning maneuver every 8 hours (treatment group)
Number of subjects: 39
Study 30181363 — intervention group
Group type: COMPARATOR
Intervention: Standard suctioning (control group)
Number of subjects: 39
Study 28011389 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of long‐acting naltrexone in prison, followed by 6 monthly injections post‐release at a community opioid treatment program
Number of subjects: 240
Study 28011389 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of long‐acting naltrexone in prison followed by 6 monthly injections post‐release at the patient's place of residence utilizing mobile medical treatment
Number of subjects: 240
Study 25992914 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy: MTX+sulfasalazine (SSZ)+hydroxychloroquine (HCQ)
Number of subjects: 487
Study 25992914 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor (anti-TNF) therapy: MTX+infliximab
Number of subjects: 487
Study 25992914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 487
Study 25992914 — intervention group
Group type: COMPARATOR
Intervention: Group B (anti-TNF therapy)
Number of subjects: 487
Study 25992914 — intervention group
Group type: COMPARATOR
Intervention: Group A (triple therapy)
Number of subjects: 487
Study 23234418 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey proteins only (OWT)
Number of subjects: 8
Study 23234418 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey proteins with glucose (OWGT)
Number of subjects: 8
Study 23234418 — intervention group
Group type: COMPARATOR
Intervention: Glucose only (OGTT)
Number of subjects: 8
Study 23234418 — intervention group
Group type: COMPARATOR
Intervention: Arginine (AST)
Number of subjects: 8
Study 23234418 — intervention group
Group type: COMPARATOR
Intervention: Glucagon (GST)
Number of subjects: 8
Study 23234418 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose (IVGTT)
Number of subjects: 8
Study 21792622 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper‐limb robotic therapy
Number of subjects: 24
Study 19458107 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg with soy extract (Genistein Soy Complex 1000 mg, twice daily for 14 days)
Number of subjects: 18
Study 19458107 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg without soy extract
Number of subjects: 18
Study 17449466 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (PA) measured by accelerometers over 8 weeks
Number of subjects: 30
Study 17449466 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sedentary behavior (TV viewing) assessed by self-report
Number of subjects: 30
Study 15459410 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (4 times daily for 10 days)
Number of subjects: 673
Study 15459410 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (single dose)
Number of subjects: 673
Study 11403509 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 2.3 g at dinner
Number of subjects: 135
Study 11403509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 10 mg at dinner
Number of subjects: 135
Study 11403509 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of colesevelam and lovastatin dosed together
Number of subjects: 135
Study 11403509 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of colesevelam and lovastatin dosed apart
Number of subjects: 135
Study 11403509 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam alone
Number of subjects: 135
Study 11403509 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin alone
Number of subjects: 135
Study 11403509 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatments
Number of subjects: 135
Study 9714974 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream (2%)
Number of subjects: 60
Study 9714974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7529391 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hetastarch (Hespan)
Number of subjects: 16
Study 7529391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard procedures for leukocyte collection
Number of subjects: 16
Study 7529391 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor modification of standard techniques
Number of subjects: 16
Study 7529391 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml of Hespan to 16 ml of blood
Number of subjects: 16
Study 7529391 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor cells, anti‐granulocyte antibody labelling or HIG
Number of subjects: 16
Study 2970744 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon (1 X 10(6) I. U.) administered orally, twice a week for two months.
Number of subjects: 2178
Study 2970744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluent alone) administered twice a week for two months.
Number of subjects: 2178
Study 31823620 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg/d)
Number of subjects: 86
Study 31823620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29037471 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating delayed cash incentive (intervention)
Number of subjects: 188
Study 29037471 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 188
Study 26304911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with docetaxel and cisplatin (CTP)
Number of subjects: 92
Study 26304911 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and cisplatin (TP)
Number of subjects: 92
Study 23277268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 445
Study 23277268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 21503782 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin® (12 units)
Number of subjects: 22
Study 21503782 — intervention group
Group type: COMPARATOR
Intervention: Dysport® (36 units)
Number of subjects: 22
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor (TNF) therapy
Number of subjects: 46
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin MRI spine score >/=11
Number of subjects: 46
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration <10 years
Number of subjects: 46
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP >/=40 mg/litre
Number of subjects: 46
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or three predictors present
Number of subjects: 46
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration >20 years, normal CRP, no active inflammatory lesion in the spine
Number of subjects: 46
Study 18006539 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI score of SI joints
Number of subjects: 46
Study 16434522 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrobot system
Number of subjects: 27
Study 16434522 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 27
Study 12616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-enhanced lunches
Number of subjects: 0
Study 12616257 — intervention group
Group type: COMPARATOR
Intervention: Traditional lunches
Number of subjects: 0
Study 12616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-enhanced foods
Number of subjects: 0
Study 12616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and soy-enhanced lunches
Number of subjects: 0
Study 10700598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia of Alzheimer type (DAT)
Number of subjects: 115
Study 10700598 — intervention group
Group type: COMPARATOR
Intervention: Vascular dementia (VD)
Number of subjects: 115
Study 10700598 — intervention group
Group type: COMPARATOR
Intervention: Non-demented (ND)
Number of subjects: 115
Study 9089127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated intervention
Number of subjects: 37
Study 9089127 — intervention group
Group type: COMPARATOR
Intervention: Lecture-group discussion intervention
Number of subjects: 37
Study 8447521 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg of ivermectin
Number of subjects: 31
Study 8447521 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg of ivermectin
Number of subjects: 31
Study 8447521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (300 and 400 micrograms/kg)
Number of subjects: 31
Study 3640743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bagging
Number of subjects: 42
Study 3640743 — intervention group
Group type: COMPARATOR
Intervention: Double-bagging
Number of subjects: 42
Study 31722475 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based Policy Optimization with Transferability Assessment (SPOTA)
Number of subjects: 0
Study 31282129 — intervention group
Group type: EXPERIMENTAL
Intervention: UFR-guided hydration with normal saline plus low-dose furosemide controlled by the RenalGuard system to maintain a high urine flow rate (>300 mL/hr)
Number of subjects: 700
Study 31282129 — intervention group
Group type: COMPARATOR
Intervention: LVEDP-guided hydration with normal saline adjusted according to LVEDP levels (5 mL kg-1 hr-1 for LVEDP ≤12 mmHg, 3 mL kg-1 hr-1 for LVEDP 13-18 mmHg, and 1.5 mL kg-1 hr-1 for LVEDP >18 mmHg)
Number of subjects: 700
Study 30218248 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic right colectomy
Number of subjects: 202
Study 30218248 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic right colectomy
Number of subjects: 202
Study 30218248 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic right colectomy (UICC stage III)
Number of subjects: 202
Study 30218248 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic right colectomy (UICC stage III)
Number of subjects: 202
Study 27264220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3×/wk, 35 min, 70%-85% VO2peak)
Number of subjects: 150
Study 27264220 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (5-20 mg qd)
Number of subjects: 150
Study 27264220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27264220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, Escitalopram, and Placebo
Number of subjects: 150
Study 24249843 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel augmented core stabilization exercise technique (ankle dorsiflexion + drawing in abdominal wall)
Number of subjects: 40
Study 22585691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy (Fluorouracil and leucovorin before, during, and after radiotherapy; Radiotherapy dose of 45 Gy)
Number of subjects: 559
Study 22585691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy
Number of subjects: 559
Study 22585691 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 559
Study 20133510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen patch (20 mg, once daily for 2 weeks)
Number of subjects: 676
Study 20133510 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (once daily for 2 weeks)
Number of subjects: 676
Study 20133510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen patch
Number of subjects: 676
Study 20133510 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen patch and Placebo patch
Number of subjects: 676
Study 18780127 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with higher dutifulness
Number of subjects: 46
Study 18780127 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians with higher vulnerability
Number of subjects: 46
Study 15937906 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 101
Study 15937906 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with carbogen breathing
Number of subjects: 101
Study 12627514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor mitotic rate (TMR) of 0 mitoses/mm(2)
Number of subjects: 3661
Study 12627514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor mitotic rate (TMR) of 1 mitosis/mm(2)
Number of subjects: 3661
Study 12627514 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR grouped using Method A (0, 1-4, 5-10, and >/= 11 mitoses/mm(2))
Number of subjects: 3661
Study 10028219 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week school-based child- and parent-focused psychosocial intervention
Number of subjects: 128
Study 10028219 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 128
Study 8721529 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ethanol
Number of subjects: 14
Study 8721529 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 14
Study 2057176 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 593
Study 2057176 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 593
Study 2057176 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 593
Study 6338610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (metronidazole and cephradine) given preoperatively
Number of subjects: 202
Study 6338610 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics given at operation only upon finding perforation, gangrene or pus formation
Number of subjects: 202
Study 29511966 — intervention group
Group type: COMPARATOR
Intervention: Integrated PFI
Number of subjects: 402
Study 29511966 — intervention group
Group type: COMPARATOR
Intervention: Combined PFI
Number of subjects: 402
Study 30100904 — intervention group
Group type: EXPERIMENTAL
Intervention: iBCE-EL (ensemble learning framework combining ERT and GB classifiers)
Number of subjects: 11543
Study 30100904 — intervention group
Group type: COMPARATOR
Intervention: Individual classifiers (ERT and GB)
Number of subjects: 11543
Study 26879651 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DP arm)
Number of subjects: 2
Study 26879651 — intervention group
Group type: COMPARATOR
Intervention: TS-1 plus cisplatin (SP arm)
Number of subjects: 2
Study 24867298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330-495 mg/day)
Number of subjects: 441
Study 24867298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 24867298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR
Number of subjects: 441
Study 23092336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - ten sessions
Number of subjects: 50
Study 23092336 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 50
Study 20175941 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/d
Number of subjects: 446
Study 20175941 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 150 mg/d
Number of subjects: 446
Study 20175941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 446
Study 17598895 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare service provided by a Diabetes Specialist Nurse (DSN)
Number of subjects: 375
Study 17598895 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare service provided by a peer supporter
Number of subjects: 375
Study 17598895 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 375
Study 15613570 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamsylate 12.5 mg/kg six hourly from within one hour of delivery for four days
Number of subjects: 268
Study 15613570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 12440799 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intensity of therapy (67% more therapy per week)
Number of subjects: 0
Study 12440799 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy intensity)
Number of subjects: 0
Study 10530655 — intervention group
Group type: EXPERIMENTAL
Intervention: IV EtOH (10% solution administered over 30 minutes)
Number of subjects: 20
Study 10530655 — intervention group
Group type: COMPARATOR
Intervention: PO EtOH (20% solution in juice administered over 10 minutes)
Number of subjects: 20
Study 7548380 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment started during operation (Cefuroxime and Tinidazole)
Number of subjects: 234